It is made available under a CC-BY-NC 4.0 International license .

1 Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis media

2 with otorrhea among Bangladeshi children

- 3 Hakka Naziat^{1,2}, Md Hafizur Rahman¹, Rajib C Das¹, Maksuda Islam¹, Shampa Saha¹, Md.
- 4 Manzoor Hussain³, Asif Sattar³, Mohammad J Uddin¹, Md. Jahangir Alam⁴, Cynthia G.
- 5 Whitney⁵, Senjuti Saha¹, Yogesh Hooda^{1, *}, Samir K Saha^{1,2, *}
- 6
- 7 1. Child Health Research Foundation, Dhaka, Bangladesh
- 8 2. Department of Microbiology, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh
- 9 3. Department of Ear, Nose and Throat, Bangladesh Shishu Hospital and Institute, Dhaka,
- 10 Bangladesh
- 11 4. Department of Pediatrics, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh
- 12 5. Rollins School of Public Health, Emory University, Atlanta, USA
- 13
- 14 * Corresponding author:
- 15 Samir K. Saha PhD FRCPath FAAM
- 16 <u>samir@chrfbd.org</u>
- 17 Child Health Research Foundation, SEL Huq Skypark, 23/2 Khilji Road, Mohammadpur, Dhaka,
- 18 1207
- 19 AND
- 20 Yogesh Hooda PhD
- 21 yhooda@chrfbd.org
- 22 Child Health Research Foundation, SEL Huq Skypark, 23/2 Khilji Road, Mohammadpur, Dhaka,
- 23 1207

It is made available under a CC-BY-NC 4.0 International license .

- 24
- 25 Keywords: Streptococcus pneumoniae, pneumococcal conjugate vaccines, otitis media,
- 26 Bangladesh

It is made available under a CC-BY-NC 4.0 International license .

27 ABSTRACT

28	In 2015, Bangladesh introduced the ten-valent pneumococcal conjugate vaccine (PCV10). This
29	study evaluates the impact of PCV10 on pneumococcal otitis media (OM), a prevalent middle
30	ear infection amongst children in low-and-middle income countries, including Bangladesh. We
31	analyzed ear swabs from OM cases with otorrhea collected at the largest pediatric hospital in
32	Dhaka, Bangladesh from April 2014 to March 2019. The study involved identifying pathogens
33	and conducting pneumococcal serotyping using the Quellung reaction.
34	
35	Four years post PCV10 introduction, the rate of detection of pneumococcus among otorrhea
36	cases decreased from 18.4% (164/892) in 2014-15 to 15.6% (581/3735) in 2018-19, reflecting a
37	15.4% reduction. Notably, vaccine serotypes (VTs) demonstrated a significant decline
38	throughout the post-PCV years, with a 44.1% reduction compared to the pre-PCV period.
39	Specific VTs like 14, 6B and 19F exhibited significant reductions of 60.2%, 57.5% and 42.9%
40	respectively. Conversely, non-vaccine serotypes (NVTs) showed non-significant increase of
41	8.6%; specifically serotype 35B showed a 70.1% increase. Administration of two or three doses
42	of PCV10 provided 84.4% protection against OM cases caused by serotypes covered by PCV10.
43	
44	This is the first report from South Asia assessing PCV's impact on pneumococcal OM. It
45	demonstrates a 15.4% reduction in pneumococcal isolation over four years and over 80%
46	efficacy of PCV10 in preventing vaccine type pneumococcal OM cases. While some vaccine
47	serotypes decreased significantly, the impact of PCV10 on overall pneumococcal OM cases was
48	dampened by increasing isolation of non-vaccine serotypes.

It is made available under a CC-BY-NC 4.0 International license .

49 INTRODUCTION

50 Streptococcus pneumoniae, or pneumococcus, is a significant bacterial pathogen responsible for 51 a range of pediatric infections worldwide, including meningitis, sepsis, pneumonia and otorrhea 52 [1,2]. Given the considerable global burden of pneumococcus-associated morbidity and 53 mortality, the World Health Organization has recommended the inclusion of pneumococcal 54 conjugate vaccine (PCV) in the routine immunization programs of all countries and assessment 55 of its impact on pneumonia, other invasive diseases, and otitis media (OM) [3,4]. In March 2015, 56 Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV10), targeting 10 57 serotypes: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F [5]. In addition, PCV10 was also 58 anticipated to provide cross-protection against 6A due to immunologic similarities with vaccine 59 serotype 6B [6–8]. Bangladesh has successfully achieved high coverage (99.2% coverage for ≥ 2 60 doses) of PCV10 across the country [9], and recent studies have reported a decline in severe 61 radiologically confirmed pneumonia amongst children under the age of five years at two sites in 62 rural Bangladesh – Mirzapur [5] and Sylhet [10]. Nevertheless, the broader impact of PCV10 on 63 other pneumococcal diseases remain to be assessed. 64 65 Otitis media is among the most common bacterial infections diagnosed in children globally, with 66 peak incidences typically within the first two years of life [11,12]. OM can range from 67 asymptomatic cases, which usually resolve or are treated without complications, to more severe 68 forms such as recurrent, nonresponsive, dry perforation, spontaneously draining, and chronic

69 suppurative OM [13]. In Bangladesh, pneumococcus is a principal cause of OM, accounting for

70 18% of all OM cases [14]. PCV10 and PCV10 \Box + \Box 6A serotypes accounted for 8% and 9% of all

71 OM cases and 46% and 49% of pneumococcus-positive cases, respectively, and these serotypes

medRxiv preprint doi: https://doi.org/10.1101/2024.09.21.24314121; this version posted September 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

72 exhibited a higher likelihood to be non-susceptible to at least one antibiotic (erythromycin and/or 73 trimethoprim-sulfamethoxazole) than nonvaccine serotypes (91% vs. 77%). A recent Cochrane 74 review including 15 publications from 11 trials reported that administration of the licensed 75 seven-valent pneumococcal conjugate vaccine (PCV7) and ten-valent PCV (PCV10) during early 76 infancy substantially reduced the relative risk of pneumococcal OM [15]. 77 78 To assess the impact of PCV10 on pneumococcal OM, our research group conducted a study to 79 identify and characterize bacterial pathogens of OM in the ear, nose, and throat (ENT) outpatient 80 department of Bangladesh Shishu Hospital and Institute from 2014 to 2019, spanning one year 81 prior to PCV10 introduction and four years following the PCV10 introduction. The study aimed 82 to determine a) the impact of PCV10 on percentage of OM cases that were pneumococcus-83 positive, b) changes in serotype distribution amongst pneumococcal OM cases, c) variations in 84 the age of infection and duration of ear discharge, and d) the antimicrobial susceptibility of 85 pneumococcus isolated from OM cases. 86 87 **METHODS** 88 The methodology employed in this study adhered strictly to those outlined in our previously 89 published baseline study [14], with no modifications. This consistency ensured the comparability 90 of results across both study periods. Details are provided below. 91 92 Study site and population 93 The study was conducted at Bangladesh Shishu Hospital and Institute (BSHI, formerly known as

94 Dhaka Shishu Hospital or DSH), the largest pediatric hospital in Bangladesh, which serves

It is made available under a CC-BY-NC 4.0 International license .

95	children from 0 to 18 years. This hospital has a dedicated out-patient department (OPD) for the
96	management of all cases seeking care for ear, nose, and throat (ENT) conditions.

97

98 Case identification and enrollment criteria

99 Children presenting with symptoms suggestive of otitis media (OM) were identified by a study

100 physician based on World Health Organization-recommended clinical criteria and otoscopic

101 examinations [16,17]. The inclusion criteria for OM cases were: (1) acute onset of one or more

102 sign/symptoms of infection such as fever, earache, ear tugging or irritability, and (2) middle ear

103 inflammation with/without middle ear effusion or spontaneous discharge (otorrhea). From

104 enrolled children with/without otorrhea (not caused by otitis externa), data on sex, age, duration

105 of discharge, and antibiotic use within the previous seven days were recorded. Informed consent

106 was obtained from caregivers for children with otorrhea to collect specimens.

107

108 Specimen collection

109 Specimens were collected from children presenting with otorrhea by trained research assistants.

110 The external auditory canal was swabbed after the removal of any debris, using a flocked swab,

and placed into a tube containing STGG medium (2% skim milk, 3% tryptone, 10% glycerol and

112 0.5% glucose). Each specimen was cultured within three hours in the laboratory and examined

113 for the presence of bacterial pathogens.

114

115 Laboratory methods

116 All specimens were cultured on blood agar with and without gentamicin (in 5% CO₂

117 environment), chocolate agar with bacitracin and MacConkey agar [17]. Growth on these

It is made available under a CC-BY-NC 4.0 International license .

selective media were examined for the presence of *Haemophilus influenzae*, *S. pneumoniae*, and
other bacterial pathogens, such as *Staphylococcus aureus*, *Moraxella catarrhalis*, *Pseudomonas spp*.

121

Pneumococcal isolates were serotyped using the Quellung reaction [18]. Antibiotic susceptibility
testing was conducted using the disc diffusion method adhering to the latest Clinical and
Laboratory Standards Institute (CLSI) guidelines [19]. Antibiotics tested included penicillin (1
µg oxacillin disc), trimethoprim-sulfamethoxazole (1/19, 25 µg disc), chloramphenicol (30 µg
disc), erythromycin (15 µg disc) and ciprofloxacin (5 µg disc). Non-susceptible pneumococcal
isolates were further tested using the E-test to determine minimum inhibitory concentrations.

128

129 Indirect cohort analysis

130 Vaccine effectiveness was assessed by comparing the vaccination status of children with 131 vaccine-type OM (VT-OM) and non-vaccine-type OM (NVT-OM). This analysis assumes that 132 vaccination does not influence the risk for non-vaccine-type disease among vaccinated 133 individuals. A recent study has shown that results derived from the indirect cohort method were 134 comparable to that of a standard case-control study [20,5], which is complex and difficult to 135 implement. VT-OM was defined as OM cases in which PCV10 serotypes or 6A were identified, 136 all other serotypes were considered NVT. All pneumococcal OM cases from April 2015 through 137 March 2019 were used for this analysis. Based on the immunization status verified by the 138 vaccination card or the caregiver's verbal confirmation (in cases where the card was not available 139 or lost), children were classified into two groups: vaccinated and unvaccinated. The unvaccinated 140 cohort included verbally confirmed non-vaccinated children and 2 - <24-month-old children who

It is made available under a CC-BY-NC 4.0 International license .

141 were not age-eligible for PCV at the time of the initial pneumococcal vaccination program (21st 142 March 2015). As Bangladesh's EPI did not have catch-up campaigns and only children aged 6 143 weeks were eligible for vaccine introduction, this strategy led to an increase of vaccine eligible 144 children gradually with time. To identify vaccine eligible children, we back calculated the 145 birthdate of children and considered those born on 7th February 2015 or later as eligible to 146 receive the 1st dose of pneumococcal vaccine at 6 weeks of age. Children who sought medical 147 care two weeks or more after receiving an initial dose were considered vaccinated. Any child 148 who came to the hospital within 14 days of receiving the 1st dose of PCV10 vaccine was 149 considered non-vaccinated. Children who received two or three doses of PCV10 were considered 150 individually for calculating vaccine impact, using children with no doses were used the 151 comparison group. We calculated the odds ratio of receipt of PCV10 dose among children who 152 had vaccine-type (PCV10) OM versus non-vaccine-type OM and used logistic regression to 153 estimate vaccine effectiveness, calculated as: Vaccine effectiveness = (1-odds ratio for PCV10 154 vaccination) x 100%.

155

156 Statistical data analysis

157 Data analyses were conducted using STATA 14.0 (Stata Corp LP, College Station, TX).

158 Epidemiological data were analyzed to elucidate the serotype distribution amongst

159 pneumococcal OM cases, duration of ear discharge, and antibiotic susceptibility profiles of *S*.

pneumoniae isolates. Common contaminants (e.g., *Bacillus spp., Staphylococcus spp.* etc.) were
excluded.

162

163 **Ethical clearance**

It is made available under a CC-BY-NC 4.0 International license .

- 164 This surveillance protocol was approved by the Institutional Review Board of Bangladesh
- 165 Institute of Child Health at BSHI. Specimens were collected as part of routine patient care.
- 166

167 **RESULTS**

- 168 From April 2014 to March 2019, a total of 5,040 OM cases were identified, with 4,279 (93.8%)
- 169 classified as otorrhea cases (Figure 1, Table 1). Ear swabs were successfully collected from
- 170 4,626 (97.8%) of these cases. A pathogen could be identified in 2,181 of the 4,626 samples
- 171 (47.1%; Supplemental Table 1). *H. influenzae* was the most frequently detected pathogen
- 172 (782/2,181; 35.8%), followed by *S. pneumoniae* (581/2,181; 26.6%), *S. aureus* (514/2,181;
- 173 23.6%) and *Pseudomonas spp.* (365/2,181; 16.7%). The trends in isolation of all detected causes
- 174 of OM cases are shown in Figure 2. In 554 out of the 2,181 culture-positive cases (25.4%),

175 multiple organisms were detected.


- 176
- Table 1: Total, PCV10-type and non-PCV10-type *S. pneumoniae* obtained from OM cases inthis study.

	April 2014- March 2015	April 2015- March 2016	April 2016- March 2017	April 2017- March 2018	April 2018- March 2019	Total post- PCV
OM episodes recorded	1111	1089	979	909	952	3929
Episodes with otorrhea	981	1061	963	840	884	3748
Specimens collected	891	1054	960	839	882	3735
Total <i>S. pneumoniae</i> detected	164	167	148	153	113	581
PCV10-type <i>S. pneumoniae</i> detected	76	72	50	28	28	178
Non-PCV10 type S.	88	95	98	125	85	403

It is made available under a CC-BY-NC 4.0 International license .

pneumoniae detected

179



180

- 181 **Figure 1:** Study design highlighting the number of yearly *S. pneumoniae* isolates collected
- during the baseline (Pre-PCV, April 2014-March 2015) and present study period (Post-PCV,
- 183 April 2015- March 2019).

184

Trends in number and serotype distribution of pneumococcal positive otorrhea cases

It is made available under a CC-BY-NC 4.0 International license .

186 From April 2014 to March 2015, 164 pneumococcal OM cases were identified. This number

- 187 reduced to 113 by April 2018 to March 2019. Over the four years following the introduction of
- 188 PCV10, the pneumococcal positivity among otorrhea cases decreased from 18.4% (164/892) to
- 189 15.6% (581/3,735) [15.4% reduction (95% CI: -1.2-28.9%); p=0.04] (Figure 3). The detection
- 190 rate for Haemophilus influenzae, Staphylococcus aureus and Pseudomonas spp was not affected
- 191 (Figure 2).






Figure 2: Trends in isolation of all cause OM, and OM caused by *H. influenzae*, *S. pneumoniae*, *S. aureus*, *Pseudomonas spp*.



- 197 CI: 25.8 57.5%, p<0.001) reduction compared to the pre-PCV period (Figure 3). Notably VTs
- 198 like 14, 6B and 19F showed significant reductions of 60.2% (95% CI: 10.7% 81.7%; p=0.009),
- 199 57.5% (95% CI: -9.01-82.3%; p=0.026) and 42.9% (95% CI: 2.6-65.5%; p=0.015), respectively


It is made available under a CC-BY-NC 4.0 International license .

- 200 (Figure 4A). No protection was seen for Serotype 1 (35.6%, 95% CI: -85.7%-83.7%; p=0.215).
- 201 While the percentage of OM cases attributable to 6A declined, this change was not statistically
- 202 significant (10.4% reduction, 95% CI: -270.7% 71.5%; p=0.405).
- 203
- 204 Non-PCV10 serotypes showed a slight increase although not significant (8.6% increase, 95% CI:
- 205 -15.4-28.2%, p=0.225), particularly 35B, which exhibited a 70.1% increase (95% CI: -18.6 % -
- 206 96.6%; p=0.04) (Figure 3, Sup Figure 1). Certain serotypes absent in the pre-PCV period were
- 207 notably present in substantial numbers during the post-PCV period, including serotype 17F
- 208 (N=13), 12F (N=9), and 18A (N=7) (Sup Figure 1).
- 209



It is made available under a CC-BY-NC 4.0 International license .

- 211 Figure 3: Percent of OM cases attributable to S. pneumoniae at Bangladesh Shishu Hospital and
- 212 Institute in Dhaka, Bangladesh from April 2014 to March 2019. Trends of all S. pneumoniae
- 213 (green), PCV10-type S. pneumoniae (VT, blue) and non-PCV10-type S. pnuemoniae (NVT, red)
- 214 isolated from OM cases is shown.
- 215
- 216



It is made available under a CC-BY-NC 4.0 International license .

- 218 **Figure 4:** Trends in the proportion of OM cases attributable to vaccine-type *S. pneumoniae* from
- April 2014 to March 2019. A) The yearly trends of percentage of VT-OM cases caused by
- 220 different VT pneumococcal serotypes included in PCV7 (pink), PCV10-GSK (dark blue),
- 221 PCV10-SII (purple), PCV13 (sky blue), PCV15 (yellow) and PCV20 (green) are shown. B) The
- estimated coverage of different PCV vaccines in the pre-PCV and post-PCV period.
- 223
- Based on our data, the estimated serotype coverage of different PCVs for OM cases amongst
- Bangladeshi infants during the pre-PCV period (2014-2015) was 37.8% for PCV7, 46.3% for
- 226 PCV10_{GSK} 62.2% for PCV10_{SII}, 72.6% for PCV13, 72.6% for PCV15 and 79.3% for PCV20.
- Four years after the introduction of PCV10 (2018-2019), the estimated serotype coverage
- 228 changed to 23.8% for PCV7, 30.6% for PCV10_{GSK}, 41.7% for PCV10_{SII}, 53.5% for PCV13,
- 229 54.4% for PCV15 and 64.5% for PCV20 (Figure 4B).
- 230

231 Age and ear discharge duration

- The median age of a child with pneumococcal OM was 10.0 months (95%CI: 9.0-13.0) in the
- pre-PCV period and 13.0 months (95% CI, 11.0-14.0) in the post-PCV period (Sup Figure 2). The
- median ear discharge duration was 5 days (95% CI: 5-6) in pre-PCV period and 5 days (95% CI:
- 4-5) in the post-PCV period (Sup Figure 3). Trend analysis found no statistical difference in the

236 median age or ear discharge duration throughout the study period.

237

238 Trends of antibiotic susceptibility of pneumococcus

- A large percentage of pneumococcal isolates were resistant to cotrimoxazole (58%) and
- 240 erythromycin (72%), while low rates of resistance were observed for penicillin (0.95%),
- chloramphenicol (5.5%) and ciprofloxacin (6.9%). No statistical difference in trends was
- 242 observed for the five antibiotics tested over the study period (Figure 4).

It is made available under a CC-BY-NC 4.0 International license .




Figure 4: Trends in antimicrobial susceptibility of *S. pneumoniae* isolates against five antibiotics
(penicillin, chloramphenicol, cotrimoxazole, erythromycin and ciprofloxacin the during the study
period. The proportion of isolates that were resistant to each drug is shown.

247

248 **PCV10 effectiveness calculation**

249 Between March 21, 2015, and March 31, 2019, 581 cases of pneumococcal OM were identified,

with 323 children being eligible for PCV10 vaccination based on their age. Among these, 178

251 (30.6%) were of vaccine-type (VT) and 403 (69.4%) were non-vaccine-type (NVT). Of the

vaccinated children (n=307), 55 had VT OM, and 252 had NVT OM. Among the unvaccinated

253 (n=274), 123 had VT OM, and 151 had NVT OM. The median age of vaccinated children and

- unvaccinated children were 7.0 and 33.5 months, respectively. The effectiveness of the 1st
- 255 PCV10 dose was 83.5% (95% CI: 29.4% 96.2%; p-value =0.011), 2nd PCV10 dose was 82.1%
- 256 (95% CI: 42.2% 94.5%; p-value =0.003) and 3rd PCV10 dose was 84.3% (95% CI: 57.1% -

It is made available under a CC-BY-NC 4.0 International license .

- 257 94.5%; p-value<0.001) (Table 2). Two or three PCV10 doses provided 84.4% (95% CI: 57.1% –
- 258 94.3%; p-value <0.001) protection against VT OM (Table 2).
- 259
- 260 **Table 2:** Indirect cohort analysis for PCV10 effectiveness calculation.

PCV doses	VT vaccinated	NVT vaccinated	vaccine effectiveness	p-value
	case/Total	case/Total	(95% CI)	
1 st dose	4/14 (28.6%)	17/24 (70.8%)	83.5% (29.4%,	0.0106
			96.2%)	
2 nd dose	11/21 (52.4%)	43/50 (86.%)	82.1% (42.2%,	0.0034
			94.5%)	
3 rd dose	46/56 (82.1%)	212/219 (96.8%)	84.8% (57.9, 94.5%)	0.0003
1 st +2 nd dose	15/25 (60%)	60/67 (89.6%)	82.5% (46.4%,	0.0020
			94.3%)	
2 nd +3 rd dose	57/67 (85.1%)	255/262 (97.3%)	84.4% (57.1%,	0.0003
			94.3%)	

261

262 **DISCUSSION**

Otitis media continues to be one of the most prevalent pediatric infections in Bangladesh, and a common cause of antibiotic prescriptions. This study, the largest case series of OM from Bangladesh - a country with a population of 170 million, examined the impact of PCV10 on pneumococcal OM. Specifically, it assessed changes in serotype distribution, duration of ear discharge, age distribution, and antibiotic susceptibility, allowing for the calculation of PCV10's effectiveness in preventing OM cases cause by vaccine serotypes. To our knowledge, this represents the first report from South Asia investigating the impact of PCVs on OM.

It is made available under a CC-BY-NC 4.0 International license .

270

271	A key finding from our study is the 15.4% reduction in pneumococcal positivity among otorrhea
272	cases over four years following the introduction of PCV10. This reduction is consistent with
273	systematic analyses of studies evaluating the impact of PCV on OM, which have reported
274	reductions ranging from 8% to 42.7% for PCV7, 5.6% to 84% for PCV10, and 2.2% to 68% for
275	PCV13 [15]. Similar results were seen from studies in Vietnam, a southeast Asian country that
276	introduced PCV10 in March 2017 and observed a ~40% reduction in pneumococcal OM cases
277	[21].
278	
279	Our data indicated a 44.1% reduction in VT OM cases, with significant decreases observed in
280	most PCV10 serotypes, including 19F, 6B, and 14. Limited cross-protection was noted for
281	serotype 6A, as reported in several studies [15,22]. In contrast, no significant difference was
282	noted for serotype 1 and low case numbers precluded effective estimates for serotypes 4, 5, and
283	7F. As expected, PCV10 had no effect on non-vaccine-type (NVT) OM cases. An increase in

certain NVT serotype's such as 35B was observed, along with a rise in the number of serotypes

285 post-vaccination, frequency of NVT OM cases did not change through the study period. These

changes in serotype distribution did not result in differences in median age, ear discharge

287 duration, or the antimicrobial susceptibility against five commonly used antibiotics.

288

An interesting trend was observed with serotype 19A, which became an increasingly common cause of invasive pneumococcal disease in some countries following the introduction of PCVs that did not include the 19A antigen [23,24]. Some studies suggested that the 19F antigen included in PCV10 could offer cross-protection for 19A [8]. Initially, we observed a reduction

It is made available under a CC-BY-NC 4.0 International license .

in the proportion of 19A cases for two years post-vaccination. Genomic sequencing of isolatescould offer an understanding of the changes in the observed phenotype [25].

295

296 Using indirect cohort analysis, the vaccine efficacy of PCV10 against VT pneumococcal OM 297 cases was calculated at 84.4%, aligning with efficacy observed in other settings, in both 298 developed and developing countries [15,21]. We also evaluated the coverage of other 299 pneumococcal vaccines, noting coverage rates of 41.7% for Serum Institute PCV10, 53.5% for 300 PCV13, 54.4% for PCV15, and 64.5% for PCV20. Incorporating PCV15 or PCV20 could 301 potentially increase the proportion of OM cases preventable by vaccination, suggesting a benefit 302 from higher valent pneumococcal vaccines in enhancing disease coverage. 303 304 Several limitations should be considered when interpreting our results. First, tympanocentesis 305 was not performed on children without otorrhea, which may have led to lack of detection of 306 certain pathogens. However, since 94% of the suspected OM cases presented with otorrhea, this 307 limitation likely had minimal, if any, impact on our analysis. Plus, the possibility of missing 308 bacterial pathogens in this study was low as we used selective and enriched (nonselective) media 309 specifically for pneumococcus and *H. influenzae*. Second, we did not test for viral pathogen in

310 the specimens, which may also play a role as co-pathogens in OM cases. Third, the study was

311 conducted at the outpatient department of a single hospital in Dhaka, the capital city of

312 Bangladesh. It is likely that severe OM cases, especially those with draining ears, are more

313 inclined to seek care at facilities like Bangladesh Shishu Hospital and Institute, which is

314 equipped to handle more complex conditions. Conversely, milder cases of OM are often

315 managed in private clinics or pharmacies. Therefore, the impact of PCV10 observed in this study

It is made available under a CC-BY-NC 4.0 International license .

might not fully represent its effect across different healthcare settings and regions within
Bangladesh.-Moreover, having only one year of pre-PCV data limited our ability to discern
longer-term trends in serotype distribution pre- and post-vaccination. Finally, the lack of a
population-based denominator in our surveillance data precludes incidence calculations.

321 Despite these limitations, our study provides robust evidence of the significant impact of PCV10 322 on pneumococcal OM cases due to vaccine serotypes in Bangladesh. Studies that detail OM 323 outcomes by specific pneumococcal serotypes are exceedingly rare, making our data particularly 324 valuable to the existing literature. This serotype-specific analysis offers a critical perspective on 325 vaccine effects, especially given the high burden of OM. In the absence of population-based 326 studies, the large number of cases identified through our hospital-based surveillance enabled a 327 detailed examination of PCV10's impact in Bangladesh. This study underscores the value of 328 serotype-specific investigations in understanding and enhancing vaccine effectiveness in 329 preventing serious health outcomes. Collectively, these findings underscore the importance of 330 continued support for PCV vaccination, highlighting its positive impact on the overall well-being 331 of children not only in Bangladesh but across the region.

332

333 AUTHOR CONTRIBUTION

334 SKS conceived the study, provided supervision, and secured funding. HN, MHR, ShS, MI

335 conducted the laboratory tests. SKS, MH and MJA supervised the sample collection. HN, RCD

and YH performed the data analysis and generated the figures. YH, SS, HN and SKS wrote the

337 manuscript. YH, SS, CJW and SKS reviewed the manuscript.

It is made available under a CC-BY-NC 4.0 International license .

339 FUNDING STATEMENT

- 340 This work was supported by Pfizer Inc (Grant number: WI209075). The funding organization had
- 341 no role in the design, implementation, data analysis, manuscript writing or decision to publish
- this study.
- 343

344 CONFLICT OF INTEREST

345 Authors declare no conflict of interest.

It is made available under a CC-BY-NC 4.0 International license .


346 **REFERENCES**


- Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of
 Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era
 of conjugate vaccines: global, regional, and national estimates for 2000–15. The Lancet
 Global Health 2018;6:e744–57. https://doi.org/10.1016/S2214-109X(18)30247-X.
- Troeger C, Blacker B, Khalil IA, Rao PC, Cao J, Zimsen SRM, et al. Estimates of the
 global, regional, and national morbidity, mortality, and aetiologies of lower respiratory
- infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of
 Disease Study 2016. The Lancet Infectious Diseases 2018;18:1191–210.
 https://doi.org/10.1016/S1473-3099(18)30310-4.
- 356 [3] Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. Wkly
 357 Epidemiol Rec 2007;82:93–104.
- Pneumococcal conjugate vaccines: WHO position paper n.d.
 https://www.who.int/publications-detail-redirect/10665-310968 (accessed April 1, 2024).
- Malaker R, Hasanuzzaman M, Hooda Y, Rahman H, Chandra Das R, Kanon N, et al.
 Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal
 disease among children <2 years old: A prospective population-based study in rural
 Bangladesh. Vaccine 2024;42:255–62. https://doi.org/10.1016/j.vaccine.2023.12.007.
- Saha S, Hasan M, Kim L, Farrar JL, Hossain B, Islam M, et al. Epidemiology and risk
 factors for pneumonia severity and mortality in Bangladeshi children <5 years of age before
 10-valent pneumococcal conjugate vaccine introduction. BMC Public Health 2016;16:1233.
 https://doi.org/10.1186/s12889-016-3897-9.
- Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737–46. https://doi.org/10.1056/NEJMoa022823.
- [8] Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any
 cross-protection against serotype 19A? BMC Pediatr 2010;10:4.
 https://doi.org/10.1186/1471-2431-10-4.
- 374 [9] DGHS Health Bulletin n.d. https://old.dghs.gov.bd/index.php/en/publications/health 375 bulletin/dghs-health-bulletin (accessed April 1, 2024).
- [10] McCollum ED, Ahmed S, Roy AD, Chowdhury NH, Schuh HB, Rizvi SJR, et al.
 Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic
 pneumonia among children in rural Bangladesh: A case-control study. Vaccine
 2020;38:6508–16. https://doi.org/10.1016/j.vaccine.2020.08.035.
- [11] Monasta L, Ronfani L, Marchetti F, Montico M, Brumatti LV, Bavcar A, et al. Burden of
 Disease Caused by Otitis Media: Systematic Review and Global Estimates. PLOS ONE
 2012;7:e36226. https://doi.org/10.1371/journal.pone.0036226.
- [12] Jin Y, Yang X, Sun H, Zhang J, Yang S, Jiang S, et al. Global, Regional, and National
 Burdens of Otitis Media From 1990 to 2019: A Population Based Study. Ear and Hearing
 n.d.:10.1097/AUD.00000000001453. https://doi.org/10.1097/AUD.0000000001453.
- [13] O'Neill P, Roberts T, Bradley Stevenson C. Otitis media in children (acute). BMJ Clin Evid
 2007;2007:0301.
- [14] Naziat H, Saha S, Islam M, Saha S, Uddin MJ, Hussain M, et al. Epidemiology of Otitis
 Media With Otorrhea Among Bangladeshi Children: Baseline Study for Future Assessment

390	of Pneumococcal Conjugate Vaccine Impact. The Pediatric Infectious Disease Journal
391	2018;37:715. https://doi.org/10.1097/INF.000000000002077.
392	[15] Sévaux JL de, Venekamp RP, Lutje V, Hak E, Schilder AG, Sanders EA, et al.
393	Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane
394	Database of Systematic Reviews 2020. https://doi.org/10.1002/14651858.CD001480.pub6.
395	[16] Rosario DC, Mendez MD. Chronic Suppurative Otitis. StatPearls, Treasure Island (FL):
396	StatPearls Publishing; 2024.
397	[17] Grevers G, Wiedemann S, Bohn J-C, Blasius R-W, Harder T, Kroeniger W, et al.
398	Identification and characterization of the bacterial etiology of clinically problematic acute
399	otitis media after tympanocentesis or spontaneous otorrhea in German children. BMC Infect
400	Dis 2012;12:312. https://doi.org/10.1186/1471-2334-12-312.
401	[18] Saha SK, Baqui AH, Darmstadt GL, Ruhulamin M, Hanif M, El Arifeen S, et al.
402	Comparison of Antibiotic Resistance and Serotype Composition of Carriage and Invasive
403	Pneumococci among Bangladeshi Children: Implications for Treatment Policy and Vaccine
404	Formulation. Journal of Clinical Microbiology 2003;41:5582–7.
405	https://doi.org/10.1128/JCM.41.12.5582-5587.2003.
406	[19] Jorgensen JH, Howell AW, Maher LA. Quantitative antimicrobial susceptibility testing of
407	Haemophilus influenzae and Streptococcus pneumoniae by using the E-test. J Clin
408	Microbiol 1991;29:109–14. https://doi.org/10.1128/jcm.29.1.109-114.1991.
409	[20] Bar-Zeev N, Swarthout TD, Everett DB, Alaerts M, Msefula J, Brown C, et al. Impact and
410	effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of
411	vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi,
412	2006–18: prospective observational time-series and case-control studies. The Lancet Global
413	Health 2021;9:e989–98. https://doi.org/10.1016/S2214-109X(21)00165-0.
414	[21] Toizumi M, Satoh C, Quilty BJ, Nguyen HAT, Madaniyazi L, Le LT, et al. Effect of
415	pneumococcal conjugate vaccine on prevalence of otitis media with effusion among
416	children in Vietnam. Vaccine 2022;40:5366–75.
417	https://doi.org/10.1016/j.vaccine.2022.07.047.
418	[22] Eskola Juhani, Kilpi Terhi, Palmu Arto, Jokinen Jukka, Eerola Mervi, Haapakoski Jaason,
419	et al. Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media. New
420	England Journal of Medicine 2001;344:403–9.
421	https://doi.org/10.1056/NEJM200102083440602.
422	[23] Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J. Emergence of a
423	multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J
424	Antimicrob Chemother 2009;64:507–10. https://doi.org/10.1093/jac/dkp210.
425	[24] Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal
426	Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–20111.
427	Emerg Infect Dis 2013;19:1074–83. https://doi.org/10.3201/eid1907.121830.
428	[25] Nakano S, Fujisawa T, Chang B, Ito Y, Akeda H, Fujita J, et al. Whole-Genome Analysis-
429	Based Phylogeographic Investigation of Streptococcus pneumoniae Serotype 19A Sequence
430	Type 320 Isolates in Japan. Antimicrob Agents Chemother 2022;66:e0139521.
431	https://doi.org/10.1128/AAC.01395-21.
432	

It is made available under a CC-BY-NC 4.0 International license .


433 SUPPLEMENTARY FIGURES





- 436 covered by PCVs from April 2014 to March 2019.
- 437


434



439 **Sup Figure 2:** Age distribution of OM cases attributable to *S. pneumoniae* during the study

440 period.

It is made available under a CC-BY-NC 4.0 International license .



441

Study period

442 **Sup Figure 3:** Ear discharge of OM cases attributable to *S. pneumoniae* during the study period.

- 443
- 444

445 **Sup Table 1:** List of all bacterial pathogens isolated from otitis media episodes detected at

446 Bangladesh Shishu Hospital and Institute during the study period: April 2015 – March 2019

447 (N=3735).

Bacterial pathogen detected	Number
Haemophilus influenzae	418
Streptococcus pneumoniae	292
Staphylococcus aureus	308
Pseudomonas spp	286
Acinetobacter spp	43
Proteus mirabilis	16
Klebsiella pneumoniae	47
Aeromonas hydrophila	1
Escherichia coli	38
Streptococcus pyogenes	101
Enterobacter spp	27
Serratia spp	6
Candida	15
Citrobacter spp	4

It is made available under a CC-BY-NC 4.0 International license .

Morganella Morganii	4
Streptococcus agalactiae	6
Klebsiella oxytoca	3
Proteus vulgaris	8
Providencia spp	4
Streptococcus pneumoniae + Haemophilus influenzae	171
Streptococcus pneumoniae + Streptococcus pyogenes	1
Streptococcus pneumoniae + Staphylococcus aureus	32
Streptococcus pneumoniae + Pseudomonas spp	14
Streptococcus pneumoniae + Acinitobacter spp	3
Streptococcus pneumoniae + Klebsiella pneumoniae	7
Streptococcus pneumoniae + Escherichia coli	5
Streptococcus pneumoniae + Enterobacter spp	1
Streptococcus pneumoniae + Providencia spp	3
Streptococcus pneumoniae + Candida	1
Streptococcus pneumoniae + Proteus mirabilis	4
Streptococcus pneumoniae + Moraxella catarrhalis	1
Haemophilus influenzae + Staphylococcus aureus	78
Haemophilus influenzae + Streptococcus agalactiae	1
Haemophilus influenzae + Moraxella catarrhalis	1
Haemophilus influenzae + Pseudomonas spp	12
Haemophilus influenzae + Streptococcus pyogenes	20
Haemophilus influenzae + Enterobacter spp	6
Haemophilus influenzae + Acinitobacter spp	3
Haemophilus influenzae + Klebsiella pneumoniae	7
Haemophilus influenzae + Escherichia coli	6
Haemophilus influenzae + Providencia spp	1
Haemophilus influenzae + Proteus mirabilis	1
Haemophilus influenzae + Streptococcus spp	1
Haemophilus influenzae + Candida	1
Streptococcus pyogenes + Acinitobacter spp	1
Streptococcus pyogenes + Klebsiella pneumoniae	2
Streptococcus pyogenes + Enterobacter spp	2
Streptococcus pyogenes + Staphylococcus aureus	15
Streptococcus pyogenes + Pseudomonas spp	7
Moraxella catarrhalis + Acinitobacter spp	1
Moraxella catarrhalis + Pseudomonas spp	1
Staphylococcus aureus + Pseudomonas spp	12
Staphylococcus aureus + Escherichia coli	9

It is made available under a CC-BY-NC 4.0 International license .

Staphylococcus aureus + Acinetobacter spp	6
Staphylococcus aureus + Enterobacter spp	10
Staphylococcus. aureus + Klebsiella pneumoniae	8
Staphylococcus aureus + Providencia spp	1
Staphylococcus aureus + Serratia spp	1
Staphylococcus aureus + Klebsiela oxytoca	1
Klebsiella pneumoniae + Escherichia coli	5
Klebsiella pneumoniae + Enterobacter spp	2
Klebsiella pneumoniae + Pseudomonas spp	10
Klebsiela oxytoca + Pseudomonas spp	1
E. coli + Pseudomonas spp	2
Enterobacter spp + Pseudomonas spp	2
Proteus mirabilis + Pseudomonas spp	4
Proteus mirabilis + Serratia spp	1
Acinitibacter sp+ Pseudomonas spp	1
Acinitibacter sp+ Citobacter spp	1
Streptococcus pneumoniae + Haemophilus influenzae + Acinitobacter spp	1
Streptococcus pneumoniae + Haemophilus influenzae + Klebsiella pneumoniae	1
Streptococcus pneumoniae + Haemophilus influenzae + Escherichia coli	2
Streptococcus pneumoniae + Haemophilus influenzae + Enterobacter spp	2
Streptococcus pneumoniae + Haemophilus influenzae + Providencia spp	1
Streptococcus pneumoniae + Haemophilus influenzae + Staphylococcus aureus	23
Streptococcus pneumoniae + Haemophilus influenzae + Pseudomonas spp	3
Streptococcus pneumoniae + Haemophilus influenzae + Streptococcus pyogenes	3
Streptococcus pneumoniae + Streptococcus pyogenes + Pseudomonas spp	2
Streptococcus pneumoniae + Proteus vulgaris + Pseudomonas spp	1
Streptococcus pneumoniae + Klebsiella pneumoniae + Pseudomonas spp	1
Streptococcus pneumoniae + Staphylococcus aureus + Acinitobacter spp	2
Streptococcus pneumoniae + Staphylococcus aureus + Klebsiella pneumoniae	1
Streptococcus pneumoniae + Staphylococcus aureus + Enterobacter spp	1
Streptococcus pneumoniae + Staphylococcus aureus + Proteus mirabilis	1
Streptococcus pneumoniae + Staphylococcus aureus +Pseudomonas spp	1
Haemophilus influenzae + Staphylococcus aureus + Escherichia coli	1
Haemophilus influenzae + Staphylococcus aureus + Acinitobacter spp	2
Haemophilus influenzae + Pseudomonas spp + Acinitobacter spp	1
Haemophilus influenzae + Pseudomonas spp + Escherichia coli	1
Haemophilus influenzae + Klebsiella pneumoniae + Acinitobacter spp	2
Haemophilus influenzae + Klebsiella pneumoniae + Enterobacter spp	1
Haemophilus influenzae + Klebsiella pneumoniae + Escherichia coli	1

It is made available under a CC-BY-NC 4.0 International license .

Haemophilus influenzae + Streptococcus pyogenes + Acinitobacter spp	1
Haemophilus influenzae + Streptococcus pyogenes + Klebsiella pneumoniae	1
Haemophilus influenzae + Streptococcus pyogenes + Staphylococcus aureus	5
Haemophilus influenzae + Streptococcus pyogenes + Streptococcus agalactiae	1
Haemophilus influenzae + Staphylococcus aureus + Pseudomonas spp	2
Streptococcus pyogenes + Staphylococcus aureus + Pseudomonas spp	1
Streptococcus pyogenes + Staphylococcus aureus + Acinitobacter spp	1
No bacterial pathogen detected	1554
Total	3735